Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601602 | 0.85 | HTT (0.66) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3460628 | 0.84 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29742388 | 0.84 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3459886 | 0.84 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2465110 | 0.84 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4626769 | 0.84 | HTT (0.58) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6570868 | 0.78 | LMNA (0.69) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19630401 | 0.77 | HTT (0.66) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10528660 | 0.77 | HTT (0.66) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8160654 | 0.77 | HTT (0.70) | HTTPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | HTT 3168/4885PDE4A 2270/4885PDE4B 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.